Nina Kadan-Lottick, MD

Associate Professor of Pediatrics (Hematology / Oncology); Medical Director, HEROS Program

Clinical Interests

  • Brain Neoplasms
  • Hematologic Diseases
  • Leukemia
  • Medical Oncology
  • Thrombocytopenia

Patient Care

Accepts new patients? Yes
Patient Type: Child
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Hematology Program | Pediatric Hematology & Oncology Program | Supportive Oncology Program

Pediatrics: Pediatric Hematology & Oncology: HEROS Survivorship Clinic | Pediatric Specialty Center

Survivorship Clinic

Yale Medical Group

Board Certifications

  • Pediatric Hematology-Oncology AB of Pediatrics (2000)

Clinical Trials

Conditions Study Title
Bones and Joints, Brain and Nervous System, Kidney, Lymphoid Leukemia, Other Male Genital Exercise Intervention Program: Feasibility Study
Umbrella Long-Term Follow-Up Protocol (COG ALTE05N1) (CIRB)
Lymphoid Leukemia Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer (COG ALTE07C1) (CIRB)
Unknown Sites Key Adverse Events after Childhood Cancer (COG ALTE03N1)
Ill-Defined Sites The Connecticut HEROS Registry
Lymphoid Leukemia Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (AALL0932) (CIRB)
Soft Tissue Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma (COG AEWS1031)(CIRB)
Brain and Nervous System Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years (COG ACNS0831) (CIRB)
Liver Treatment of Children with All Stages of Hepatoblastoma: A Groupwide, Phase III Study (COG AHEP0731) (CIRB)
Bones and Joints, Brain and Nervous System, Hodgkin's Lymphoma, Kidney, Leukemia, not otherwise specified, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Male Genital, Soft Tissue Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Network (COG ACCRN07) (CIRB)
Soft Tissue A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol (COG 9902)
Brain and Nervous System Neuroblastoma Biology Studies (COG ANBL00B1) {CIRB}
Ill-Defined Sites Neuropsychological Functioning in Children Treated for Cancer
Brain and Nervous System ANBL0032: PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (Ch14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
Leukemia, other A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML): A Groupwide Phase III Study ( COG ACCLO933) (CIRB)
Kidney National Wilms Tumor Late Effects Study (POG 9442)
Leukemia, not otherwise specified A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789, NSC#606869) in the Very Hish Risk Stratum (COG AALL1131)(CIRB)
Myeloid and Monocytic Leukemia AAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for patients with High Allelic Ratio FLT3/ITD; A Groupwide II/III Study
Soft Tissue ANBL1221 A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#683864, IND#61010) or Chimeric 14.18 Antibody (ch 14.18) (NSC#623408, IND#4308) in Children with Refractory or Progressive Neuroblastoma
Leukemia, other ANHL1131 Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of Rituximab efficacy and safety in high risk patients

Edit this profile